Hyperfine Q3 GAAP EPS of -$0.06 beats by $0.02; revenue of $5.96M misses by $0.75M
Hyperfine reported Q3 GAAP EPS of -$0.06, beating estimates by $0.02, with revenue of $5.96M, missing by $0.75M. The company's net loss narrowed to $5.98M from $11.02M year-over-year, and operating loss decreased by 19%.
How this was made

The 30-second read
Why it matters
This is a straightforward earnings-print recap with no additional forward-looking guidance or deal information in the provided text.
Market read
Traders may reassess near-term fundamentals based on the beat/miss and loss narrowing, but the lack of guidance limits decision impact.
What to watch
The brief does not include guidance, cash balance, or backlog details, which are often the real drivers after a revenue miss.
Background
The article summarizes Hyperfine’s Q3 results, noting EPS beat and revenue miss, plus narrowing GAAP net loss versus the prior year quarter.
Ticker impact
Hyperfine reported Q3 GAAP EPS of -$0.06 and revenue of $5.96M, with EPS beating and revenue missing by stated amounts.
Likely mixed reaction, with pressure from the revenue miss offset by the EPS beat.
The article provides the company’s own quarterly results with explicit beat/miss figures, but no guidance or new catalyst beyond the print.
Market effects
Limited read-through to the broader medical device or diagnostics space because the article contains only a single-company quarterly print.
No clear regional spillover beyond US small-cap biotech/healthtech sentiment.
Minimal global relevance; no international regulatory or partnership developments mentioned.
Counterpoint
If investors focus on narrowing GAAP net loss and operating loss, the EPS beat could outweigh the revenue miss for valuation support.
Key entities
- companyHyperfine
HYPR, reported Q3 GAAP EPS and revenue, with losses narrowing year over year.


